{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:25:34Z","timestamp":1789759534035,"version":"4.0.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.jbspin.2017.04.007","type":"journal-article","created":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T17:31:51Z","timestamp":1493400711000},"page":"47-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["New structural formats of therapeutic antibodies for rheumatology"],"prefix":"10.1016","volume":"85","author":[{"given":"Christophe","family":"Dumet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9my","family":"Pottier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Gouilleux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Watier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2017.04.007_bib0005","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/annrheumdis-2014-206237","article-title":"The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region","volume":"74","author":"van Schie","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2017.04.007_bib0010","first-page":"2204","article-title":"Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity","volume":"34","author":"Davis","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2017.04.007_bib0015","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jri.2016.04.284","article-title":"Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer","volume":"116","author":"Porter","year":"2016","journal-title":"J Reprod Immunol"},{"key":"10.1016\/j.jbspin.2017.04.007_bib0020","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1051\/medsci\/200925121053","article-title":"Neonatal Fc receptor, key control of immunoglobulins biodistribution","volume":"25","author":"Magdelaine-beuzelin","year":"2009","journal-title":"Medecine\/Sciences"},{"key":"10.1016\/j.jbspin.2017.04.007_bib0025","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/nbt1337","article-title":"From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice","volume":"25","author":"Jakobovits","year":"2007","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jbspin.2017.04.007_bib0030","series-title":"Modifications in the IgG4 Fc portion of therapeutics in patents: opportunities for a twisting IgG subclass","author":"Pottier","year":"2016"},{"key":"10.1016\/j.jbspin.2017.04.007_bib0035","doi-asserted-by":"crossref","first-page":"332","DOI":"10.4161\/mabs.1.4.9122","article-title":"Human immunoglobulin allotypes: possible implications for immunogenicity","volume":"1","author":"Jefferis","year":"2009","journal-title":"MAbs"},{"key":"10.1016\/j.jbspin.2017.04.007_bib0040","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/FPC.0b013e32832a06bf","article-title":"IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab","volume":"19","author":"Magdelaine-Beuzelin","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jbspin.2017.04.007_bib0045","doi-asserted-by":"crossref","first-page":"607","DOI":"10.4049\/jimmunol.1501780","article-title":"IgG1 Allotypes influence the pharmacokinetics of therapeutic monoclonal antibodies through FcRn binding","volume":"196","author":"Ternant","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.jbspin.2017.04.007_bib0050","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/ni846","article-title":"CTLA-4-Ig regulates tryptophan catabolism in vivo","volume":"3","author":"Grohmann","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jbspin.2017.04.007_bib0055","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.clim.2007.08.019","article-title":"Abatacept modulates human dendritic cell-stimulated T-cell proliferation and effector function independent of IDO induction","volume":"126","author":"Davis","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jbspin.2017.04.007_bib0060","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1073\/pnas.87.1.162","article-title":"Influence of the hinge region on complement activation, C1q binding, and segmental flexibility in chimeric human immunoglobulins","volume":"87","author":"Tan","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jbspin.2017.04.007_bib0065","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1126\/science.1144603","article-title":"Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange","volume":"317","author":"van der Neut Kolfschoten","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.jbspin.2017.04.007_bib0070","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1080\/19420862.2015.1046665","article-title":"Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activation","volume":"7","author":"van den Bremer","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.jbspin.2017.04.007_bib0075","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.molimm.2012.12.005","article-title":"IgG2 disulfide isoform conversion kinetics","volume":"54","author":"Liu","year":"2013","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jbspin.2017.04.007_bib0080","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ccell.2014.11.001","article-title":"Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies","volume":"27","author":"White","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbspin.2017.04.007_bib0085","doi-asserted-by":"crossref","first-page":"16206","DOI":"10.1074\/jbc.M709988200","article-title":"Structural and functional characterization of disulfide isoforms of the human IGg2 subclass","volume":"283","author":"Dillon","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jbspin.2017.04.007_bib0090","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Papp Ka","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2017.04.007_bib0095","series-title":"Anti-IL-17A\/IL-17F cross-reactive antibodies and methods of use thereof","author":"Masternak","year":"2009"},{"key":"10.1016\/j.jbspin.2017.04.007_bib0100","series-title":"Antibody molecules which bind IL-17A and IL-17F","author":"Adams","year":"2008"},{"key":"10.1016\/j.jbspin.2017.04.007_bib0105","first-page":"219","volume":"33","author":"Sheridan","year":"2015","journal-title":"Amgen's bispecific antibody puffs across finish line"},{"key":"10.1016\/j.jbspin.2017.04.007_bib0110","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/art.38896","article-title":"Combined inhibition of tumor necrosis factor \u03b1 and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody","volume":"67","author":"Fischer","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2017.04.007_bib0115","first-page":"S543","article-title":"Pre-clinical proof-of-concept of ALX-0761, a nanobody neutralizing both IL-17a and f in a cynomolgus monkey collagen induced arthritis model","volume":"65","author":"Vanheusden","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2017.04.007_bib0120","doi-asserted-by":"crossref","first-page":"R138","DOI":"10.1186\/ar4319","article-title":"Murine analogues of etanercept and of F8-IL10 inhibit the progression of collagen-induced arthritis in the mouse","volume":"15","author":"Doll","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2017.04.007_bib0125","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1002\/ijc.23408","article-title":"A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo","volume":"122","author":"Villa","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jbspin.2017.04.007_bib0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrrheum.2015.17","article-title":"Trojan horses and guided missiles: targeted therapies in the war on arthritis","volume":"11","author":"Ferrari","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jbspin.2017.04.007_bib0135","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/cei.12739","article-title":"Clinical efficacy of a new CD28-targeting antagonist of T cell co-stimulation in a non-human primate model of collagen-induced arthritis","volume":"183","author":"Vierboom","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jbspin.2017.04.007_bib0140","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nature16057","article-title":"Novel antibody\u2013antibiotic conjugate eliminates intracellular S.\u00a0aureus","volume":"527","author":"Lehar","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jbspin.2017.04.007_bib0145","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1021\/jacs.5b00620","article-title":"An immunosuppressive antibody-drug conjugate","volume":"137","author":"Wang","year":"2015","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.jbspin.2017.04.007_bib0150","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/19420862.2016.1255520","article-title":"Rethinking the INN system for therapeutic antibodies","volume":"9","author":"Pottier","year":"2017","journal-title":"MAbs"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X17300842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X17300842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T03:52:59Z","timestamp":1535860379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X17300842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S1297319X17300842"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2017.04.007","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New structural formats of therapeutic antibodies for rheumatology","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2017.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}